Naito Masahito, Yamamoto Tomoya, Hara Shinsuke, Shimamoto Chikao, Miwa Yoshihiro
Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
Chemotherapy. 2017;62(1):23-29. doi: 10.1159/000445866. Epub 2016 May 28.
Hand-foot syndrome (HFS) is a common side effect that has a high occurrence rate with capecitabine (Cape) chemotherapy. However, little is known about the risk factors of developing HFS under the Cape regimen. Our aim was to examine these risk factors.
A univariate analysis was used to determine the risk factors associated with developing HFS, and we calculated the effect sizes between the patients who developed HFS compared to those who did not.
Of the 52 patients enrolled in our research, 24 (46.2%) developed HFS. This group was significantly associated with hemoglobin (Hb) values (p < 0.001), and the effect size (1.21) was more than moderate. The receiver operating characteristic curve analysis confirmed 12 mg/dl Hb as the best diagnostic cut-off value for developing HFS. The sensitivity and specificity were 75.5 and 88.2%, respectively. Patients who had Hb values of 12 or below who developed HFS had longer median times without HFS compared to patients with high Hb values (115 vs. 75 days, p = 0.30, hazard ratio = 1.42, 95% CI 0.73-2.76) and a greater area under the Kaplan-Meier curves (p < 0.05).
This research suggests that the Hb value is an important factor for developing HFS.
手足综合征（HFS）是卡培他滨（Cape）化疗常见的副作用，发生率较高。然而，关于在Cape方案下发生HFS的危险因素知之甚少。我们的目的是研究这些危险因素。
采用单因素分析确定与发生HFS相关的危险因素，并计算发生HFS的患者与未发生HFS的患者之间的效应量。
在我们研究纳入的52例患者中，24例（46.2%）发生了HFS。该组与血红蛋白（Hb）值显著相关（p<0.001），效应量（1.21）大于中等程度。受试者工作特征曲线分析确定12mg/dl Hb为发生HFS的最佳诊断临界值。敏感性和特异性分别为75.5%和88.2%。与高Hb值的患者相比，Hb值为12或更低且发生HFS的患者无HFS的中位时间更长（115天对75天，p=0.30，风险比=1.42，95%CI 0.73-2.76），且Kaplan-Meier曲线下面积更大（p<0.05）。
本研究表明Hb值是发生HFS的一个重要因素。
